Saturday 17 October 2026
Export IMNN’s income statement to Excel — free account
Imunon, Inc.
IMNN Healthcare Biotechnology
Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.02
0.04
−3.77%
Follow IMNN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.25 | 1.90 | 1.15 | 1.44 | |
Current Ratio |
1.73 | 2.32 | 1.59 | 1.82 | |
Net Debt/EBITDA |
1.59 | 2.15 | 1.16 | 0.52 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 36.92% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 1.32 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.30 | 0.87 | 0.94 | 1.07 | |
Capex/Depreciation |
0.00 | (0.02) | 0.00 | (0.33) | |
Interest Coverage |
— | — | — | (36.11) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.51) | (1.72) | (0.79) | (0.58) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(1.51) | (1.72) | (0.79) | (0.59) | |
Cash per Share |
1.78 | 4.14 | 0.95 | 1.31 | |
Shareholders Equity per Share |
1.39 | 3.33 | 0.67 | 0.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.39 | 3.33 | 0.67 | 0.80 | |
Free Cash Flow |
(4.44) | (3.66) | (3.99) | (3.09) | |
Working Capital |
3.06 | 6.10 | 2.45 | 3.91 | |
Capital Expenditures |
0.00 | 0.00 | — | (0.07) | |
Net Current Asset Value |
2.35 | 5.50 | 1.96 | (2.11) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Payables |
1.74 | 1.35 | 1.41 | 1.68 | |
Average Assets |
11.69 | 11.00 | 7.44 | 11.89 | |
Average Common Equity |
6.14 | 5.65 | 1.91 | 2.30 |
Columns are period end dates